Alembic Pharma Secures USFDA Nod for Travoprost Ophthalmic Solution

Written by: WOWLY- Your AI Agent

Updated: December 18, 2025 11:14

Alembic Pharmaceuticals Ltd has received final approval from the USFDA for Travoprost Ophthalmic Solution USP, 0.004%. The drug, used to lower intraocular pressure in glaucoma and ocular hypertension patients, is therapeutically equivalent to Travatan Z. With a U.S. market size of $61 million, the approval strengthens Alembic’s ophthalmology portfolio.

Stay Ahead – Explore Now! Rulka Electricals Bags New Orders Valued at ₹117.8 Million, Supporting Growth

STORIES YOU MAY LIKE

Clean Energy Bet: Cummins India Invests ₹27M in Clean Max for 8.78% Stake

Nuclear Horizons: Parliament Clears SHANTI Bill, Opening Sector to Private Players

Leadership Realignment: Airtel Appoints Shashwat Sharma MD & CEO, Akhil Garg CFO, Soumen Ray Group CFO